CytoDyn Inc. (OTCMKTS:CYDY) Sees Large Growth in Short Interest

CytoDyn Inc. (OTCMKTS:CYDY) saw a significant increase in short interest during the month of January. As of January 31st, there was short interest totalling 22,639,300 shares, an increase of 6.4% from the January 15th total of 21,272,500 shares. Based on an average daily volume of 11,699,700 shares, the short-interest ratio is presently 1.9 days.

CytoDyn Trading Up 0.2 %

Shares of OTCMKTS:CYDY traded up $0.00 during trading on Tuesday, reaching $0.22. 1,991,689 shares of the company traded hands, compared to its average volume of 4,342,034. The business’s fifty day moving average is $0.16 and its 200-day moving average is $0.15. CytoDyn has a 52-week low of $0.10 and a 52-week high of $0.32. The firm has a market capitalization of $267.36 million, a price-to-earnings ratio of -21.73 and a beta of 0.01.

CytoDyn Company Profile

CytoDyn Inc, a clinical-stage biotechnology company, engages in the development of treatments for multiple therapeutic indications. The company is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19, human immunodeficiency virus (HIV), Metabolic dysfunction-associated steatohepatitis (MASH), and solid tumors in oncology, such as metastatic triple-negative breast cancer.